Up to $287 million Series D1 backs CORXEL’s bid to bring a pill-based obesity and cardiometabolic treatment to a global stage.
The race to make GLP-1 therapy easier to take – and therefore easier to scale – is accelerating. CORXEL Pharmaceuticals has secured up to $287 million in Series D1 funding to advance CX11, its oral small-molecule GLP-1 receptor agonist, and broaden its cardiometabolic pipeline. With injectable GLP-1s already reshaping obesity and diabetes care, the next competitive frontier is oral delivery – lowering friction for long-term use in conditions that quietly compress healthspan.
Founded in Shanghai in 2019 and now headquartered in New Jersey, CORXEL represents a new kind of biopharma company: one that has grown alongside China’s biotech ecosystem and is now exporting that innovation to the rest of the world. The latest round, supported by a syndicate of global healthcare investors including RTW Investments, TCG Crossover (TCGX), RA Capital Management, SR One Capital Management, HBM Healthcare Investments and SymBiosis, marks a turning point in that journey [1].
CORXEL is positioning itself at the center of one of the most competitive and consequential races in modern medicine: oral GLP-1 therapies for obesity, diabetes and broader cardiometabolic disease.
To understand why this matters, it helps to step back from the science. GLP-1 drugs work by helping the body regulate appetite and blood sugar. In practice, they help people feel fuller sooner, eat less and manage glucose levels more effectively. These therapies have already reshaped obesity and diabetes treatment, but most require regular injections.
CORXEL’s lead program, CX11, takes a different route. It is a small-molecule pill designed to activate the same biological pathway, without the needle [2]. Think of it as the difference between needing a regular clinic visit and being able to take a daily tablet at home. The goal is not just convenience, but reach, which lowers friction for patients who may need these treatments for years, if not decades.
The Series D1 proceeds are expected to support CX11’s ongoing Phase 2 trial in obese and overweight patients in the United States, a planned global Phase 2 study in people with type 2 diabetes, and early preparations for Phase 3 trials. In parallel, Vincentage, the China-based biotech that originally developed the molecule, is already running a Phase 3 study in China.
CORXEL acquired the ex-China rights to CX11 in 2024, transforming what began as a domestic program into a globally ambitious one.
CORXEL’s trajectory is a major shift since the company began life as Jixing Pharmaceuticals, initially focused on in-licensing molecules developed elsewhere and bringing them to the Chinese market. Over time, that strategy flipped.
As China’s biotech sector matured, CORXEL evolved with it, building its own pipeline, securing global rights to key assets and rebranding to reflect its outward-looking ambitions. Today, the company operates across New Jersey, Copenhagen and Shanghai, with around 85 employees supporting multiregional clinical programs.
“This investment is one of the most significant milestones for CORXEL since its founding, as it not only fuels our effort to accelerate the global development of industry-leading therapies against cardiometabolic diseases but also propels the company to a new orbit of growth,” said Sandy Mou, Board Executive Director and CEO of CORXEL [1].
The financing also brings new voices into the company’s governance, with SR One, TCGX and other investors set to appoint three new representatives to CORXEL’s board.
Beyond obesity: a cardiometabolic platform
While CX11 sits at the center of attention, CORXEL is not positioning itself as a single-asset company. It is also advancing JX10, a small-molecule therapy for acute ischemic stroke, currently in a registrational Phase 2/3 study, as well as JX09, an experimental hypertension drug in early clinical development [3].
Together, these programs point to a broader strategy: addressing cardiometabolic disease not as isolated conditions, but as interconnected drivers of long-term health decline. Obesity, diabetes, hypertension and stroke rarely exist alone. They compound over time, accelerating biological aging and eroding healthspan.
Extending life without addressing cardiometabolic health is a losing proposition. Interventions that slow or reverse metabolic damage are increasingly seen as foundational to healthier aging.
The oral GLP-1 field is intensely competitive. Major pharmaceutical companies and independent biotechs alike are racing to bring pill-based alternatives to market. Yet the size of CORXEL’s raise suggests that investors still see room for differentiation and for new entrants with credible clinical execution.
More broadly, the financing highlights a change in the source of innovation. CORXEL’s evolution – from Shanghai startup to globally active biopharma – reflects how longevity-relevant therapies are no longer confined to traditional Western hubs.
As capital flows toward cardiometabolic programs with global reach, the future of longevity will be built across borders, and increasingly, around diseases that quietly shape how we age.
[1] https://www.corxelbio.com/en/press-releases/corxel-announces-287-million-series-d1-financing-to-further-advance-its-cardiometabolic-pipeline-including-oral-small-molecule-glp-1-receptor-agonist/
[2] https://www.corxelbio.com/en/press-releases/corxel-announces-first-patient-enrolled-in-the-us-phase-2-trial-of-cx11-in-obese-and-overweight-patients/
[3] https://www.corxelbio.com/en/press-releases/corxel-announces-china-national-medical-products-administration-approval-of-the-clinical-trial-application-for-orion-the-global-registrational-study-of-jx10-in-patients-with-acute-ischemic-stroke/
